# A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

> **NCT06161584** · — · ACTIVE_NOT_RECRUITING · sponsor: **Apellis Pharmaceuticals, Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Geographic Atrophy

## Interventions

- **DRUG:** Pegcetacoplan

## Key facts

- **NCT ID:** NCT06161584
- **Lead sponsor:** Apellis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-28
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161584, "A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06161584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*